Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27195353 | 0.87 | HDAC8 (0.44) | HDAC6HDAC8PRMT5OGG1KDM4E | |
| SCHEMBL30724696 | 0.87 | HDAC8 (0.44) | HDAC6HDAC8PRMT5OGG1KDM4E | |
| SCHEMBL22092818 | 0.86 | HDAC6 (0.44) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL29878704 | 0.84 | ENPP2 (0.51) | HDAC1HDAC6HDAC3HDAC2ENPP2 | |
| SCHEMBL22057278 | 0.84 | ENPP2 (0.51) | HDAC1HDAC6HDAC3HDAC2ENPP2 | |
| SCHEMBL23501092 | 0.83 | HDAC8 (0.41) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL29878495 | 0.83 | HDAC8 (0.41) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL22092797 | 0.81 | HDAC8 (0.43) | HDAC6HDAC8PRMT5ENPP2 | |
| SCHEMBL28653403 | 0.81 | HDAC8 (0.43) | HDAC6HDAC8PRMT5ENPP2 | |
| SCHEMBL23500773 | 0.80 | HDAC8 (0.41) | HDAC1HDAC6HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692083-A1 | NOVEL AZABICYCLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN, COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024205327-A1 | NOVEL AZABICYCLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN, COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-10-03 | — | — | WO | disclosed |
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4074711-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| CN-114901658-A | Nitrogen-containing heterocyclic ring autotaxin inhibitor, and composition and application thereof | 四川海思科制药有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021115375-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | 四川海思科制药有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115375-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | 四川海思科制药有限公司 | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | ENPP2, NMT2, NMT1 | HDAC1 1593/4885HDAC6 849/4885HDAC3 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.